Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

Part of paid clinical trials in Los Angeles, California.

Sponsor
Duke University
Study ID
NCT00003463
Phase
PHASE1
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • carmustine — DRUG
  • irinotecan hydrochloride — DRUG
  • polifeprosan 20 with carmustine implant — DRUG
  • surgical procedure — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.

Key Dates

Start date
Jul 31, 1998
Status verified
Feb 2013
Primary completion
Jul 31, 2002
Completion
Jul 31, 2002

Study Design

Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Jonsson Comprehensive Cancer Center, UCLALos AngelesCalifornia90095-1781-
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-

Find similar trials in Los Angeles, CA

By research site
Jonsson Comprehensive Cancer Center, UCLA· Los Angeles, CADuke Comprehensive Cancer Center· Durham, NC

Related Studies